NBoMe
Psicodélicos2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Estructura molecular
Efectos
Diagrama corporal
2-4 horas
6-10 horas
15-45 minutos (sublingual)
Sublingual: ~40-60%, Oral: <10%
Hígado
Renal (metabolitos)
Timeline farmacocinético
Riesgos para la salud — Calculadora de dosis
Advertencias
- Extremadamente tóxico incluso en dosis bajas
- Ventana terapéutica muy estrecha
- A menudo vendido falsamente como LSD
- Muerte reportada con dosis de pocos miligramos
- Efectos impredecibles y potencialmente fatales
Combinaciones peligrosas
Descripción
El 25-NBOMe es una clase de compuestos fenetilamínicos que actúan como agonistas potentes de los receptores de serotonina 5-HT2A, generando efectos alucinógenos. Estos compuestos, como el 25I-NBOMe y 25C-NBOMe, son extremadamente potentes y peligrosos, con efectos adversos graves como psicosis, rabdomiólisis y daño renal. A menudo se comercializan como sustitutos del LSD, pero con un riesgo elevado de sobredosis y muerte.
Referencias
Datos farmacológicos obtenidos de PubChem (CID: 10251906) — NIH National Library of Medicine
Evidencia científica y ensayos clínicos
The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior.
Kościuk Z et al. · Pharmacological reports : PR · 2026
Repeated administration of the synthetic cannabinoid AKB48 induces serotonergic neuroadaptation in male and female mice: behavioural and immunohistochemical evidence.
Corli G et al. · Neuropharmacology · 2026
Sublethal Concentrations of 2C-I and 25I-NBOMe Designer Drugs Impact Caenorhabditis elegans Development and Reproductive Behavior.
Gil-Martins E et al. · International journal of molecular sciences · 2025
The effect of low-dose psilocybin on brain neurotransmission and rat behavior.
Bysiek A et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2025
Acute Effects of the Psychedelic Phenethylamine 25I-NBOMe in C57BL/6J Male Mice.
Bilel S et al. · International journal of molecular sciences · 2025
The role of mitochondrial dysfunction and calcium dysregulation in 2C-I and 25I-NBOMe-induced neurotoxicity.
Gil-Martins E et al. · Chemico-biological interactions · 2025
Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assay.
Gampfer TM et al. · Journal of pharmaceutical and biomedical analysis · 2024
Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.
Hadley M et al. · Journal of psychoactive drugs · 2025
Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor.
Deventer MH et al. · Archives of toxicology · 2023
Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs.
Tirri M et al. · Frontiers in psychiatry · 2022